NCT02779777Phase 2Terminated

Tipifarnib in Subjects With Myelodysplastic Syndromes

Study sponsor: Kura Oncology, Inc. · KURA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2018-08-28Actual
Enrollment · participants16Actual
Source updated2024-07-31Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.